Susquehanna International Group, LLP Fate Therapeutics Inc Transaction History

Susquehanna International Group, LLP

$823 Billion
Q3 2025

A detailed history of Susquehanna International Group, LLP transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 178,927 shares of FATE stock, worth $171,769. This represents 0.0% of its overall portfolio holdings.

Number of Shares

178,927

Previous 289,232 38.14%

Holding current value

$171,769

Previous $323,000 30.34%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$0.92 - $1.3 $101,480 - $143,396	-110,305 Reduced 38.14%	178,927 $225,000
Q2 2025 Aug 14, 2025	BUY	$0.68 - $1.67 $76,072 - $186,826	111,872 Added 63.08%	289,232 $323,000
Q1 2025 May 14, 2025	BUY	$0.79 - $1.87 $55,257 - $130,799	69,946 Added 65.12%	177,360 $140,000
Q4 2024 Feb 14, 2025	BUY	$1.61 - $3.35 $81,551 - $169,687	50,653 Added 89.24%	107,414 $177,000
Q3 2024 Nov 14, 2024	BUY	$3.12 - $5.57 $10,820 - $19,316	3,468 Added 6.51%	56,761 $198,000

Q2 2024 Aug 15, 2024	SELL	$3.26 - $7.08 $130,540 - $283,504	-40,043 Reduced 42.9%	53,293 $174,000
Q1 2024 May 07, 2024	SELL	$3.54 - $8.35 $209,472 - $494,094	-59,173 Reduced 38.8%	93,336 $685,000
Q4 2023 Feb 14, 2024	SELL	$1.65 - $3.94 $466,327 - $1.11 Million	-282,623 Reduced 64.95%	152,509 $570,000
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $101,456 - $253,139	-50,226 Reduced 10.35%	435,132 $922,000
Q2 2023 Aug 11, 2023	SELL	$4.76 - $6.59 $1.84 Million - $2.55 Million	-386,856 Reduced 44.35%	485,358 $2.31 Million
Q1 2023 May 16, 2023	BUY	$4.24 - $11.12 $3.54 Million - $9.29 Million	835,597 Added 2281.99%	872,214 $4.97 Million
Q4 2022 Feb 14, 2023	SELL	$9.86 - $23.83 $883,702 - $2.14 Million	-89,625 Reduced 70.99%	36,617 $369,000
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $208,085 - $356,633	9,890 Added 8.5%	126,242 $2.83 Million
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $1.09 Million - $2.61 Million	61,539 Added 112.27%	116,352 $2.88 Million
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $1.52 Million - $3.1 Million	-51,390 Reduced 48.39%	54,813 $2.13 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $956,273 - $1.29 Million	19,989 Added 23.19%	106,203 $6.21 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $3.15 Million - $5.09 Million	53,206 Added 161.19%	86,214 $5.11 Million
Q2 2021 Aug 11, 2021	SELL	$67.25 - $92.52 $615,270 - $846,465	-9,149 Reduced 21.7%	33,008 $2.87 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $2.07 Million - $3.36 Million	-28,622 Reduced 40.44%	42,157 $3.48 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $2.38 Million - $6.31 Million	-62,505 Reduced 46.9%	70,779 $6.44 Million
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $669,172 - $891,202	22,005 Added 19.77%	133,284 $5.33 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $1.54 Million - $2.68 Million	75,969 Added 215.15%	111,279 $3.82 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $1.04 Million - $1.92 Million	-60,347 Reduced 63.09%	35,310 $784,000
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $281,497 - $435,806	21,023 Added 28.17%	95,657 $1.87 Million
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $326,324 - $474,615	21,094 Added 39.4%	74,634 $1.16 Million
Q2 2019 Aug 16, 2019	BUY	$15.61 - $20.44 $478,368 - $626,383	30,645 Added 133.85%	53,540 $1.09 Million
Q2 2018 Aug 14, 2018	SELL	$9.16 - $13.48 $50,737 - $74,665	-5,539 Reduced 19.48%	22,895 $260,000
Q1 2018 May 15, 2018	SELL	$6.3 - $13.77 $130,410 - $285,039	-20,700 Reduced 42.13%	28,434 $278,000
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $193,587 - $326,249	49,134	49,134 $300,000

Others Institutions Holding FATE

# of Institutions

155

Shares Held

81.5M

Call Options Held

46.4K

Put Options Held

17.5K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $93.1M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Fate Therapeutics Inc Transaction History